Plasma lipids metabolism in mild cognitive impairment and Alzheimer’s disease

Costa, Alana C.; Joaquim, Helena Passarelli Giroud; Forlenza, Orestes Vicente; Talib, Leda Leme; Gattaz, Wagner F.

doi:10.1080/15622975.2017.1369566

Cited by 20 publications

(17 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, this was not especially surprising, as many authors have repeatedly reported inconsistent results and unsatisfactory validation of metabolomicsbased biomarkers. [40][41][42][43] Growing evidence points that one of the most important challenges for biomarker validation studies in the metabolomics field could be the high intra-and interindividual variability of the human metabolome, which can arise from genetic (e.g., gender), temporal (e.g., circadian rhythm), environmental (e.g., dietary habits) or microbial (e.g., eubiosis/dysbiosis) factors. [44] This variability may result in different, but analogous, metabolic responses (e.g., different metabolites from the same metabolic pathway) to a given physiological or pathological stimuli.…”

Section: Discussionmentioning

confidence: 99%

Food and Microbiota Metabolites Associate with Cognitive Decline in Older Subjects: A 12‐Year Prospective Study

González‐Domínguez

Castellano‐Escuder

Carmona

et al. 2021

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope: Diet is considered an important modulator of cognitive decline and dementia, but the available evidence is, however, still fragmented and often inconsistent. Methods and Results: The article studies the long-term prospective Three-City Cohort, which consists of two separate nested case-control sample sets from different geographic regions (Bordeaux, n = 418; Dijon, n = 424). Cognitive decline is evaluated through five neuropsychological tests (Mini-Mental State Examination, Benton Visual Retention Test, Isaac's Set Test, Trail-Making Test part A, and Trail-Making Test part B).The food-related and microbiota-derived circulating metabolome is studied in participants free of dementia at baseline, by subjecting serum samples to large-scale quantitative metabolomics analysis. A protective association is found between metabolites derived from cocoa, coffee, mushrooms, red wine, the microbial metabolism of polyphenol-rich foods, and cognitive decline, as well as a negative association with metabolites related to unhealthy dietary components, such as artificial sweeteners and alcohol. Conclusion: These results provide insight into the early metabolic events that are associated with the later risk to develop cognitive decline within the crosstalk between diet, gut microbiota and the endogenous metabolism, which can help identify potential targets for preventive and therapeutic strategies to preserve cognitive health.

show abstract

Section: Discussionmentioning

confidence: 99%

Food and Microbiota Metabolites Associate with Cognitive Decline in Older Subjects: A 12‐Year Prospective Study

González‐Domínguez

Castellano‐Escuder

Carmona

et al. 2021

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

“…With links between cardiovascular disease and AD being drawn, as well as some promising results from lifestyle intervention on cognitive performance [67], lipid evaluation has become another area of interest in the search for blood-based biomarkers of AD. Two recent pilot studies have shown levels of lipids to differ significantly between mutation carriers and non-carriers in a study on familial AD [68], as well as AD and controls in a sporadic AD study [69]. However, neither study was able to use these profiles to accurately discriminate between the respective classes.…”

Section: Metabolomicsmentioning

confidence: 93%

Blood-based molecular biomarkers for Alzheimer’s disease

2019

View full text Add to dashboard Cite

A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology. This may be related in part to the limited capacity of the current health systems to select those people likely to have AD pathology in order to confirm the diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative review, we summarize the literature on candidate blood tests for AD that could be implemented in primary care settings and used for the effective identification of individuals at increased risk of AD pathology, who could be referred for potential inclusion in clinical trials or future approved treatments following additional testing. We give an updated account of blood-based candidate biomarkers and biomarker panels for AD-related brain changes. Our analysis centres on biomarker candidates that have been replicated in more than one study and discusses the need of further studies to achieve the goal of a primary care-based screening algorithm for AD.

show abstract

“…A new technique, which uses brain-focused ultrasound (FUS) ( Costa, Joaquim, Forlenza, Talib, & Gattaz, 2019 ) to sonicate systematically administered microbubbles, can reversibly and locally disrupt tight junctions ( Shang, Wang, Liu, Zhang, & Xue, 2011 ; Sheikov, McDannold, Sharma, & Hynynen, 2008 ) and increase active transcytosis in the BBB ( Sheikov et al, 2006 ), allowing antibody transport from the blood to specific brain regions. This method was found to be safe in non-human primates ( McDannold, Arvanitis, Vykhodtseva, & Livingstone, 2012 ; Nwagwu et al, 2020 ), and recently in humans ( Abrahao et al, 2019 ; Carpentier et al, 2016 ).…”

Section: Fcrn and Cellular Barriersmentioning

confidence: 99%

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Ojaimi

Blin

Lamamy

et al. 2022

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Antibody-based therapeutics have become a major class of therapeutics with over 120 recombinant antibodies approved or under review in the EU or US. This therapeutic class has experienced a remarkable expansion with an expected acceleration in 2021–2022 due to the extraordinary global response to SARS-CoV2 pandemic and the public disclosure of over a hundred anti-SARS-CoV2 antibodies. Mainly delivered intravenously, alternative delivery routes have emerged to improve antibody therapeutic index and patient comfort. A major hurdle for antibody delivery and efficacy as well as the development of alternative administration routes, is to understand the different natural and pathological barriers that antibodies face as soon as they enter the body up to the moment they bind to their target antigen. In this review, we discuss the well-known and more under-investigated extracellular and cellular barriers faced by antibodies. We also discuss some of the strategies developed in the recent years to overcome these barriers and increase antibody delivery to its site of action. A better understanding of the biological barriers that antibodies have to face will allow the optimization of antibody delivery near its target. This opens the way to the development of improved therapy with less systemic side effects and increased patients’ adherence to the treatment.

show abstract

Plasma lipids metabolism in mild cognitive impairment and Alzheimer’s disease

Abstract: Lipids metabolites in plasma might indirectly indicate changes in neuronal membrane and this deregulation can outline the transition between healthy and diseased brains.

Cited by 20 publications

References 53 publications

Food and Microbiota Metabolites Associate with Cognitive Decline in Older Subjects: A 12‐Year Prospective Study

Food and Microbiota Metabolites Associate with Cognitive Decline in Older Subjects: A 12‐Year Prospective Study

Blood-based molecular biomarkers for Alzheimer’s disease

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Contact Info

Product

Resources

About